By Fineline Cube 
China’s Shanghai Pharmaceuticals Holding Ltd (SPH, HKG: 2607, SHA: 601607) announced this week a strategic collaboration with Novartis China, a unit of Swiss pharmaceutical giant Novartis (NYSE: NVS). The partnership focuses on multiple ophthalmic products, aiming to expand Novartis China’s market penetration for anti-infective and glaucoma treatments. By leveraging SPH’s integrated marketing expertise and broad market coverage, the collaboration seeks to enhance patient access to high-quality therapies in non-core markets.
Collaboration Details
Novartis China will utilize SPH’s full-channel marketing capabilities to accelerate the adoption of its ophthalmic products. In return, SPH will benefit from Novartis China’s brand influence and product strengths, supported by their proven clinical efficacy and safety.
Cardiovascular Health Management Center
On the same day, Novartis China, SPH Holding, and SPH Health Commerce inaugurated the Cardiovascular Health Management Center. This initiative integrates hospital and community resources to establish a standardized pathway for hyperlipidemia diagnosis and treatment. By combining SPH’s retail strengths with AI-driven digital technologies and an online hospital platform, the center aims to create a novel value-based pharmacy service ecosystem for chronic cardiovascular patients.-Fineline Info & Tech